{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:57:38Z","timestamp":1790629058460,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of intravenous glucocorticoids (IVGCs) and low-dose acetylsalicylic acid (ASA) in giant cell arteritis (GCA) remains controversial, with limited evidence and heterogeneous guideline recommendations. We conducted an international survey to characterise current practice patterns, clinical equipoise, and trial design priorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional online survey was distributed internationally to clinicians involved in GCA care between December 2025 and January 2026. Questions addressed demographics, prescribing practices, motivations and barriers, and preferred outcomes for clinical trials evaluating ASA and IVGCs. Descriptive analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 155 respondents from five continents were included, predominantly rheumatologists (51.0%) and ophthalmology specialists (33.5%). ASA was initiated in a minority of patients (median 15%), primarily for stroke prevention, with major barriers including lack of disease-specific evidence and bleeding risk. Clinical equipoise regarding ASA was reported by 69.5%, and 71.6% expressed interest in trial participation. IVGCs were widely used for visual involvement, particularly permanent vision loss, though substantial variability existed in indications and dosing. Equipoise for IV versus oral glucocorticoids was reported by 68.5%, with strong interest in trial participation (71.2%). Across both interventions, respondents prioritised clinically meaningful outcomes such as stroke, contralateral vision loss, and major adverse cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This international survey demonstrates significant heterogeneity and persistent clinical uncertainty in the use of ASA and IVGCs in GCA. High levels of equipoise and willingness to participate in trials highlight the urgent need for randomised studies to inform evidence-based practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04912-4","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:41:31Z","timestamp":1790581291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["International practice patterns and beliefs concerning intravenous methylprednisolone and low-dose aspirin in giant cell arteritis"],"prefix":"10.1038","author":[{"given":"Mats","family":"Junek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-4437","authenticated-orcid":false,"given":"Susan P.","family":"Mollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Makhzoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"4912_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02599-w","volume":"13","author":"J-P Makhzoum","year":"2024","unstructured":"Makhzoum J-P, Baati Y, Tanase O, Mendel A, Pagnoux C, Ross C. Antiplatelet therapy to prevent ischemic events in giant cell arteritis: protocol for a systematic review and meta-analysis. Syst Rev. 2024;13:173.","journal-title":"Syst Rev"},{"key":"4912_CR2","doi-asserted-by":"publisher","unstructured":"Pelletier EKC, Ducharme-B\u00e9nard S, Makhzoum JP. Risk factors for acute coronary syndrome in patients with giant cell arteritis: a scoping review. Ther Adv Musculoskeletal Dis 2026;18.1759720X261425813. https:\/\/doi.org\/10.1177\/1759720X261425813.","DOI":"10.1177\/1759720X261425813"},{"key":"4912_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105641","volume":"91","author":"R Fore","year":"2024","unstructured":"Fore R, Liozon E, Dumonteil S, Sene T, Heron E, Lacombe V, et al. BOB-ACG study: Pulse methylprednisolone to prevent bilateral ophthalmologic damage in giant cell arteritis. A multicentre retrospective study with propensity score analysis. Jt Bone Spine. 2024;91:105641.","journal-title":"Jt Bone Spine"},{"key":"4912_CR4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/rheumatology\/keae459","volume":"64","author":"H Henningson","year":"2025","unstructured":"Henningson H, Hammar B, Mohammad AJ. The use of intravenous methylprednisolone in giant cell arteritis: a population-based study. Rheumatol (Oxf). 2025;64:2083\u201390.","journal-title":"Rheumatol (Oxf)"},{"key":"4912_CR5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3899\/jrheum.2025-0459","volume":"52","author":"ML Junek","year":"2025","unstructured":"Junek ML, Chanchlani R, Rodriguez AR, Khalidi N, Molnar AO. Assessment of Giant Cell Arteritis-Associated Visual Outcomes at a Tertiary Hospital in Ontario, Canada. J Rheumatol. 2025;52:1274\u201380.","journal-title":"J Rheumatol"},{"key":"4912_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","volume":"112","author":"H Danesh-Meyer","year":"2005","unstructured":"Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005;112:1098\u2013103. https:\/\/doi.org\/10.1016\/j.ophtha.2005.01.036.","journal-title":"Ophthalmology"},{"key":"4912_CR7","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/art.20171","volume":"50","author":"G Nesher","year":"2004","unstructured":"Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332\u20137.","journal-title":"Arthritis Rheum"},{"key":"4912_CR8","volume":"2014","author":"SP Mollan","year":"2014","unstructured":"Mollan SP, Sharrack N, Burdon MA, Denniston AK. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev. 2014;2014:CD010453.","journal-title":"Cochrane Database Syst Rev"},{"key":"4912_CR9","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and takayasu arteritis. Arthritis Rheumatol. 2021;73:1349\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"4912_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kez672","volume":"59","author":"SL Mackie","year":"2020","unstructured":"Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatol (Oxf). 2020;59:e1\u2013e23.","journal-title":"Rheumatol (Oxf)"},{"key":"4912_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330.","journal-title":"Ann Rheum Dis"},{"key":"4912_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard-2022-223429","volume":"83","author":"C Dejaco","year":"2024","unstructured":"Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2024;83:48\u201357. https:\/\/doi.org\/10.1136\/ard-2022-223429.","journal-title":"Ann Rheum Dis"},{"key":"4912_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/ard-2024-225515","volume":"84","author":"NJM Chaddock","year":"2025","unstructured":"Chaddock NJM, Harden CJ, Sorensen L, Mathieson HR, Zulcinski M, Lawson CA, et al. UK GCA Consortium. Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis. Ann Rheum Dis. 2025;84:329\u201340. https:\/\/doi.org\/10.1136\/ard-2024-225515.","journal-title":"Ann Rheum Dis"},{"key":"4912_CR14","doi-asserted-by":"publisher","first-page":"e266579","DOI":"10.1001\/jamanetworkopen.2026.6579","volume":"9","author":"M Beydon","year":"2026","unstructured":"Beydon M, Hajage D, Gu\u00e9don AF, Carrat F, Seror R, Tubach F. Low-dose aspirin for cardiovascular disease primary prevention in patients with giant cell arteritis. JAMA Netw Open. 2026;9:e266579 https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.6579.","journal-title":"JAMA Netw Open"},{"key":"4912_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.7861\/clinmed.2022-0041","volume":"22","author":"R Piccus","year":"2022","unstructured":"Piccus R, Hansen MS, Hamann S, Mollan SP. An update on the clinical approach to giant cell arteritis. Clin Med (Lond). 2022;22:107\u201311. https:\/\/doi.org\/10.7861\/clinmed.2022-0041.","journal-title":"Clin Med (Lond)"},{"key":"4912_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1613849.","journal-title":"N Engl J Med"},{"key":"4912_CR17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/bjophthalmol-2016-309955","volume":"101","author":"S Dean","year":"2017","unstructured":"Dean S, Mathers JM, Calvert M, Kyte DG, Conroy D, Folkard A, et al. The patient is speaking\u201d: discovering the patient voice in ophthalmology. Br J Ophthalmol. 2017;101:700\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309955.","journal-title":"Br J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04912-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04912-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04912-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:03:01Z","timestamp":1790625781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04912-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":17,"alternative-id":["4912"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04912-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJ has received consultation or advisory fees from Otsuka and AbbVie; unrestricted educational grants from Roche. SPM is funded by a Southeastern Ontario Academic Medical Organization chair in research and innovation. She reports consultancy fees (NovoNordisk); advisory board fees (Ocular therapeutix, Domp\u00e9); speaker fees (Teva, AbbVie); Travel (AbbVie, Essilorluxottica, European Alliance of Associations for Rheumatology, Oculis); Receipt of equipment (Heidelberg Engineering). SPM is a section editor at Eye (Springer). JPM receives a salary award from the Fonds de Recherche du Qu\u00e9bec and research grants from the Canadian Institutes of Health Research. He has received consultation or presentation fees from Roche, Otsuka, GlaxoSmithKline, AstraZeneca, Amgen, Fresenius Kabi and Sanofi and is an investigator in clinical trials funded by the Vasculitis Clinical Research Consortium (VCRC), Janssen, Novartis, and AbbVie outside the submitted work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Institutional ethics approval was not required for this survey. Participation was voluntary, and respondents provided consent for the presentation of aggregated results.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}